Colchicine therapy, evaluated in a review including a 51-patient multicenter study with up to 10 years of follow-up, is a promising adjunct to conventional treatment for recurrent pericarditis.
BACKGROUND: The most troublesome complication of acute pericarditis is recurrent episodes of pericardial inflammation, occurring in 15% to 32% of cases. The cause of the recurrence is usually unknown, although in some cases it may be traced to viral infection or may be a consequence of coronary artery bypass grafting. The optimal method for prevention has not been fully established; accepted modalities include nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressive agents, and pericardiectomy. METHODS AND RESULTS: Based on the proven efficacy of colchicine therapy for familial Mediterranean fever (recurrent polyserositis), several small studies have used colchicine successfully to prevent recurrence of acute pericarditis after failure of conventional treatment. Recently, we reported the results from the largest multicenter international study on 51 patients who were treated with colchicine to prevent further relapses and who were followed up for < or = 10 years. CONCLUSIONS: In light of new trial data that have accumulated in the past decade, we review the evidence for the efficacy and safety of colchicine for the prevention of recurrent episodes of pericarditis. Clinical and personal experience shows that colchicine may be an extremely promising adjunct to conventional treatment and may ultimately serve as the initial mode of treatment, especially in idiopathic cases.
Adler et al. (Tue,) conducted a review in Recurrent pericarditis (n=51). Colchicine vs. Conventional treatment was evaluated on Prevention of recurrent episodes of pericarditis. Colchicine therapy, evaluated in a review including a 51-patient multicenter study with up to 10 years of follow-up, is a promising adjunct to conventional treatment for recurrent pericarditis.